Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients.

Background: Therapeutic options for patients with treatment-resistant schizophrenia are limited, and combination treatment with atypical antipsychotic drugs is an often used strategy. We tested ...

New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to ...

serotonergic and adrenergic receptors – failed to improve the positive and negative schizophrenia symptom scale (PANSS) compared to conventional therapy in patients with treatment-resistant ...

Erin Crown, PA-C, CAQ-Psychiatry is a paid consultant of ®2024 Otsuka America Pharmaceutical, Inc. and Lundbeck, manufacturers of ABILIFY ASIMTUFII® (aripiprazole) and ABILIFY MAINTENA ...

The thousands of people with treatment resistant schizophrenia who have invested time, effort and trust may be heartened to know that some direction has emerged from the not quite so random activity.

Unsupervised use of hallucinogens like LSD is high, posing significant risks. However, LSD is being clinically tested for treating anxiety and so far seems effective.

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

Jane Jepson remembers when her son, Nick, first came back home in 2017. He was working as a bellman, traveling across the ...

The death of a mother at the hands of her son was described as “tragic” by a Calgary judge, who found the 32-year-old not criminally responsible.